Table 2.
UIP Cohort Treatment Exposure During Study Period
| Therapy | NAC Exposed (n = 58) | NAC Unexposed (n = 235) | p-value |
|---|---|---|---|
| NAC monotherapy | 29 (50) | 0 (0) | < 0.001 |
| Immunosuppressant exposurea | 15 (25.9) | 54 (22.8) | 0.64 |
| Prednisone | 15 (25.9) | 53 (22.6) | 0.59 |
| Azathioprine | 8 (13.8) | 9 (3.8) | 0.004 |
| Mycophenolate mofetil | 3 (6.0) | 3 (2.8) | 0.38 |
| Anti-fibrotic exposure | 11 (18.9) | 29 (12.3) | 0.19 |
| Pirfenidone | 10 (17.2) | 24 (10.2) | 0.13 |
| Nintedanib | 1 (1.8) | 6 (2.6) | 1 |
Abbreviations: UIP usual interstitial pneumonia, NAC N-acetylcysteine
aAzathioprine/prednisone or mycophenolate/prednisone